Menu

Top Stories

PPTA statement says plasma protein products are safe, not affected by Zika virus

PPTA statement says plasma protein products are safe, not affected by Zika virus
Saturday, September 24, 2016
The Plasma Protein Therapeutics Association (PPTA) has issued a statement saying that the safety of plasma protein therapies is not affected by the Zika virus (ZIKV). "According to recommendations from health authorities, measures such as halting collections, donor deferral or testing are not necessary for plasma which is further manufactured into plasma protein therapies," the PPTA said in...
Divider

Arrowhead begins Phase 2 trial of possible Alpha-1 liver treatment

Tuesday, September 6, 2016
California-based Arrowhead Pharmaceuticals Inc. announced Tuesday that it has begun a Phase 2 clinical study of ARC-AAT, the company's potential treatment for liver disease in people with Alpha-1 Antitrypsin Deficiency (AATD), using the...
Divider

Kamada Phase 2 trial shows promising results for inhaled augmentation

Wednesday, August 31, 2016
Kamada has released the results of a clinical trial showing that inhaled augmentation produces higher levels of alpha-1 protein in the airways than traditional intravenous augmentation. Mark Brantly, MD The company says the study’s...
Divider

ATS editorial warns against unregulated stem cell “treatments”

Monday, August 22, 2016
The Annals of the ATS, a publication of the American Thoracic Society, has published an editorial that warns against the use of unregulated, expensive stem cell remedies to treat severe respiratory diseases. The editorial, written by Laertis...
Divider

UMass gets 5-year, $11 million research grant for Alpha-1 gene therapy

Thursday, August 11, 2016
The National Heart, Lung, and Blood Institute (NHLBI) has awarded an $11 million, five-year grant to the University of Massachusetts Medical School to study new approaches to Alpha-1 gene therapy. Members of the UMass program project grant...
Divider

Alpha-1 Foundation leaders go to The White House to advocate better forms of detection and treatment for Alphas

Thursday, July 14, 2016
WASHINGTON – Alpha-1 Foundation representatives traveled to The White House this week to advocate better forms of detection and treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1) under President Barack Obama’s Precision Medicine...
Divider

New targeted gene therapy could lead to improved treatments for Alphas

Monday, July 11, 2016
Researchers at Boston University are examining whether delivering gene therapy directly to the lungs of mice could improve treatment for Alphas. Andrew Wilson, MD Current therapies add normal alpha-1 antitrypsin (AAT) protein into the...
Divider

Researchers show off “gene editing” technique to Alpha-1 support group

Friday, June 3, 2016
Researchers are looking for a way to genetically “edit” out Alpha-1 in much the same way that a writer corrects misspelled words, or a film editor cuts old frames and splices in new ones. Members of the Alpha-1 Mainers Support Group...
Divider

Pope calls for "empathy" in treating people with rare diseases

Tuesday, May 3, 2016
Pope Francis told participants in a Vatican health summit on Friday that a renewed sense of empathy should fuel their work and research, particularly regarding treatment for people who have rare diseases. Pope Francis “It is fundamentally...
Divider

The Alpha-1 Project extends funding for NIH-NCATS fellowship for a third year

Wednesday, April 13, 2016
The Alpha-1 Project has announced that it will extend funding for the postdoctoral fellowship at the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) for a third year. The extension follows...
Divider

Alpha-1-To-One magazine Spring issue in your mail now

Wednesday, March 30, 2016
The Spring 2016 issue of Alpha-1-To-One magazine has been mailed to well over 20,000 people with free subscriptions, and will soon be available online. This is the cover story, "In search of new therapies for Alpha-1,"  part of a...
Divider

Kamada applies to market inhaled Alpha-1 therapy in Europe

Tuesday, March 29, 2016
Kamada has submitted a Marketing Authorization Application with the European Medicines Agency (EMA), seeking permission to market its inhaled therapy for Alpha-1 Antitrypsin Deficiency in Europe. The EMA, the European equivalent of the U.S. Food...
Divider

Conference to address ethical issues in rare disease research

Wednesday, March 23, 2016
People with rare diseases such as Alpha-1 deserve treatments that are proven to be safe and effective. Christine Grady, PhD But unlike more common diseases, rare diseases offer fewer patients who are able to participate in clinical trials to...
Divider
123456

Article Search

Enter keywords in text box and click Search button for results.